ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GSK Gsk Plc

1,602.50
7.50 (0.47%)
Last Updated: 11:12:21
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  7.50 0.47% 1,602.50 1,602.50 1,603.00 1,612.50 1,597.00 1,600.50 581,720 11:12:21
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 13.46 66.33B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,595p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,820.00p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £66.33 billion. Gsk has a price to earnings ratio (PE ratio) of 13.46.

Gsk Share Discussion Threads

Showing 21601 to 21624 of 33300 messages
Chat Pages: Latest  876  875  874  873  872  871  870  869  868  867  866  865  Older
DateSubjectAuthorDiscuss
15/7/2020
19:58
Better day today!
delboy45
15/7/2020
15:44
1755p on its way.
montyhedge
15/7/2020
15:41
Orchard Therapeutics said it is in license agreements with GlaxoSmithKline PLC.

The agreements are for use of Glaxo's lentiviral stable cell line technology for Orchard's investigational hematopoietic stem cell gene therapies for Wiskott Aldrich syndrome and transfusion-dependent beta thalassemia.

Orchard said it plans to submit a biologics license application and marketing authorization application for OTL-103 for the Wiskott Aldrich syndrome in the U.S. and EU, respectively, in 2021.

tradermichael
15/7/2020
13:09
On a day where this is (currently) 2.7% up, AZN has to rub my nose in it with a 4.7% rise. That's just bad manners really.
rikky72
15/7/2020
10:38
Seems everything Astra and GSK putting forward getting approval.All good news.
montyhedge
15/7/2020
08:04
GlaxoSmithKline PLC said Wednesday that a U.S. Food and Drug Administration committee has voted in favor of its belantamab mafodotin antibody drug as therapy for the treatment of relapsed or refractory multiple myeloma.The FDA's oncologic drugs advisory committee voted in favor of a positive benefit-risk profile for the drug to help patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, the British pharmaceutical company said. The FDA will consider the recommendation of the committee but isn't obligated to follow it, GSK said.Belantamab mafodotin isn't currently approved for use anywhere in the world, the company said.spud
spud
11/7/2020
15:14
Sepsis already kills around 40,000 people in the UK each year.
Does not tend to hit the headlines as it's a constant.

In Europe nearly 700,000 people die from Sepsis every year.


I got a nick from shaving two years ago which became infected. It took two different antibiotics (Flucloxacillin did not work). Had to stay on Augmentin for a month, one week at a full dose, 3 weeks at a reduced level, to clear it.

essentialinvestor
11/7/2020
14:39
The chief executive of Glaxosmithkline has warned that drug companies must overcome a systemic industry issue to combat the rising threat of antibiotic-resistant infections.

Emma Walmsley, one of the pharmaceuticals industry’s most senior leaders, said that the coronavirus pandemic had shown “the world needs to be better prepared for global health threats”, but antimicrobial resistance was another such threat that “left untackled risks taking us back to a time when a simple cut could become lethal”.

She said that there was limited funding for research “because the market doesn’t reflect the value antibiotics deliver to society and therefore doesn’t incentivise investment”.



for full report (but behind a paywall).

grahamburn
11/7/2020
12:18
Getting a dividend on the doormat every 13 weeks while we wait for 2250p, not to bad.
montyhedge
11/7/2020
10:27
One of the most undervalued listed Pharmaceutical companies imo. Either we're all wrong to be invested here or the Market has got this upside down and adding at this level will be shown to be genius 3 years down the track. Either way, it ain't going pop so I'll back my judgement and keep taking the dividend. spud
spud
10/7/2020
21:57
rikky,most investors are thinking like you hence the share price is deteriorating .
abdullla
10/7/2020
18:46
I don't see this as either as great investment or a terrible one but there are much better opportunities for growth elsewhere. If they can't show pipeline growth and then cut the dividend then, yes, I see £10-12 region a distinct possibility. Although it's some way off still the split makes me uncomfortable. Anything reasonably north of £17 and I'm seriously considering exiting entirely.
rikky72
10/7/2020
17:24
Spud my dear there is no more money left on my trees!
abdullla
10/7/2020
16:52
Another great buying opportunity imo! Look back on this price in 3 years and you'll be asking yerself why you didn't buy more..spud
spud
10/7/2020
16:46
It’s a serial under performer, zero growth share becos the drug pipeline is poor, contrast with Astra, it’s also got too much debt. I don’t see any way that the dividend isn’t cut and if it is this is down 150 points on the day. Stick to the S&P and big cash cow tech, the ftse 350 is for shorting purposes only. First brexit then covid, the U.K. set to be the most hammered country in the g7 thanks to the Boris and his cronies fiasco, no happy ending I’m afraid. Bail out.
porsche1945
10/7/2020
16:28
Sounds like a good strategy and I wont panic Ihope!!
jamesretlaw
10/7/2020
16:16
As far as the corona vaccine is concerned I think GSK Is playing safe,like they are in it with the rest of them but they are also not in it, they obviously don't want to gamble with the share holders funds,whatever the outcome GSK has Adjuvant which all others will need and money will start to flow in the direction of GSK again.
abdullla
10/7/2020
15:56
James, if you are trading GSK there are multiple factors at play here, from FX
to wider UKX levels and sentiment also plays a part.

The price is being pushed around on COVID vaccine news atm, which is
borderline ridiculous as GSK are late to the race and there are likely SFA in
returns to be made from this. As a leading global vaccine manufacturer I can
understand why they are attempting to make a contribution to the COVID effort.
Inaction on this might look rather odd and arguably have reputational damage

essentialinvestor
10/7/2020
15:40
Well i can only hold on now and hope it rises to 1620 again
jamesretlaw
10/7/2020
15:33
James a bit of sixth sense I guess.
abdullla
10/7/2020
15:11
You were right 1570 how did you know abdulla
jamesretlaw
10/7/2020
15:11
Sadly you didn't listen to me and went for the knife but still I wish you and GSK a fast recovery.
abdullla
10/7/2020
14:52
I’m new to this and feel awful too..... trying to hold on but all in the red and not sure what to do 😩
dawnie03
10/7/2020
14:50
OUCH this looks awful for me .... ;o)
tradermichael
Chat Pages: Latest  876  875  874  873  872  871  870  869  868  867  866  865  Older